-
Something wrong with this record ?
RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia
AR. Poetsch, DB. Lipka, T. Witte, R. Claus, P. Nöllke, M. Zucknick, C. Olk-Batz, S. Fluhr, M. Dworzak, B. De Moerloose, J. Starý, M. Zecca, H. Hasle, M. Schmugge, MM. van den Heuvel-Eibrink, F. Locatelli, CM. Niemeyer, C. Flotho, C. Plass,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2006 to 1 year ago
PubMed Central
from 2010
Europe PubMed Central
from 2010 to 1 year ago
PubMed
25147919
DOI
10.4161/epi.29941
Knihovny.cz E-resources
- MeSH
- Drug Resistance, Neoplasm * MeSH
- CpG Islands MeSH
- Child MeSH
- Leukemia, Myelomonocytic, Juvenile diagnosis metabolism pathology MeSH
- Infant MeSH
- Humans MeSH
- Chromosomes, Human, Pair 7 MeSH
- DNA Methylation * MeSH
- Adolescent MeSH
- Monosomy MeSH
- Mutation MeSH
- Child, Preschool MeSH
- Prognosis MeSH
- Promoter Regions, Genetic MeSH
- Protein Isoforms genetics metabolism MeSH
- ras GTPase-Activating Proteins genetics metabolism MeSH
- Protein Tyrosine Phosphatase, Non-Receptor Type 11 genetics metabolism MeSH
- Gene Silencing MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Aberrant DNA methylation at specific genetic loci is a key molecular feature of juvenile myelomonocytic leukemia (JMML) with poor prognosis. Using quantitative high-resolution mass spectrometry, we identified RASA4 isoform 2, which maps to chromosome 7 and encodes a member of the GAP1 family of GTPase-activating proteins for small G proteins, as a recurrent target of isoform-specific DNA hypermethylation in JMML (51% of 125 patients analyzed). RASA4 isoform 2 promoter methylation correlated with clinical parameters predicting poor prognosis (older age, elevated fetal hemoglobin), with higher risk of relapse after hematopoietic stem cell transplantation, and with PTPN11 mutation. The level of isoform 2 methylation increased in relapsed cases after transplantation. Interestingly, most JMML cases with monosomy 7 exhibited hypermethylation on the remaining RASA4 allele. The results corroborate the significance of epigenetic modifications in the phenotype of aggressive JMML.
Aarhus University Hospital Skejby
Charles University and University Hospital Motol Praha
Czech Pediatric Hematology Working Group
Department of Pediatric Hematology Oncology
Department of Pediatric Oncology Hematology
Dept of Pediatric Hematology and Oncology
Dept of Pediatric Hematology Oncology
Division of Epigenomics and Cancer Risk Factors
Division of Pediatric Hematology Oncology
Dutch Children's Oncology Group
St Anna Children's Hospital and Children's Cancer Research Institute
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15023108
- 003
- CZ-PrNML
- 005
- 20230331095215.0
- 007
- ta
- 008
- 150709s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4161/epi.29941 $2 doi
- 035 __
- $a (PubMed)25147919
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Poetsch, Anna R $u Division of Epigenomics and Cancer Risk Factors (C010); German Cancer Research Center; Heidelberg, Germany.
- 245 10
- $a RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia / $c AR. Poetsch, DB. Lipka, T. Witte, R. Claus, P. Nöllke, M. Zucknick, C. Olk-Batz, S. Fluhr, M. Dworzak, B. De Moerloose, J. Starý, M. Zecca, H. Hasle, M. Schmugge, MM. van den Heuvel-Eibrink, F. Locatelli, CM. Niemeyer, C. Flotho, C. Plass,
- 520 9_
- $a Aberrant DNA methylation at specific genetic loci is a key molecular feature of juvenile myelomonocytic leukemia (JMML) with poor prognosis. Using quantitative high-resolution mass spectrometry, we identified RASA4 isoform 2, which maps to chromosome 7 and encodes a member of the GAP1 family of GTPase-activating proteins for small G proteins, as a recurrent target of isoform-specific DNA hypermethylation in JMML (51% of 125 patients analyzed). RASA4 isoform 2 promoter methylation correlated with clinical parameters predicting poor prognosis (older age, elevated fetal hemoglobin), with higher risk of relapse after hematopoietic stem cell transplantation, and with PTPN11 mutation. The level of isoform 2 methylation increased in relapsed cases after transplantation. Interestingly, most JMML cases with monosomy 7 exhibited hypermethylation on the remaining RASA4 allele. The results corroborate the significance of epigenetic modifications in the phenotype of aggressive JMML.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a lidské chromozomy, pár 7 $7 D002897
- 650 _2
- $a CpG ostrůvky $7 D018899
- 650 12
- $a metylace DNA $7 D019175
- 650 12
- $a chemorezistence $7 D019008
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a umlčování genů $7 D020868
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a juvenilní myelomonocytární leukemie $x diagnóza $x metabolismus $x patologie $7 D054429
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a monozomie $7 D009006
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a promotorové oblasti (genetika) $7 D011401
- 650 _2
- $a protein - isoformy $x genetika $x metabolismus $7 D020033
- 650 _2
- $a tyrosinfosfatasa nereceptorového typu 11 $x genetika $x metabolismus $7 D054592
- 650 _2
- $a proteiny aktivující GTPasu ras $x genetika $x metabolismus $7 D020703
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lipka, Daniel B $u Division of Epigenomics and Cancer Risk Factors (C010); German Cancer Research Center; Heidelberg, Germany.
- 700 1_
- $a Witte, Tania $u Division of Epigenomics and Cancer Risk Factors (C010); German Cancer Research Center; Heidelberg, Germany.
- 700 1_
- $a Claus, Rainer $u Division of Epigenomics and Cancer Risk Factors (C010); German Cancer Research Center; Heidelberg, Germany.
- 700 1_
- $a Nöllke, Peter $u Division of Pediatric Hematology-Oncology; University Medical Center; Freiburg, Germany.
- 700 1_
- $a Zucknick, Manuela $u Division of Biostatistics; German Cancer Research Center; Heidelberg, Germany.
- 700 1_
- $a Olk-Batz, Christiane $u Division of Pediatric Hematology-Oncology; University Medical Center; Freiburg, Germany.
- 700 1_
- $a Fluhr, Silvia $u Division of Pediatric Hematology-Oncology; University Medical Center; Freiburg, Germany.
- 700 1_
- $a Dworzak, Michael $u St. Anna Children's Hospital and Children's Cancer Research Institute; Department of Pediatrics; Medical University of Vienna; Vienna, Austria.
- 700 1_
- $a De Moerloose, Barbara $u Dept. of Pediatric Hematology-Oncology; Ghent University Hospital; Ghent, Belgium.
- 700 1_
- $a Starý, Jan $u Dept. of Pediatric Hematology and Oncology; 2nd Faculty of Medicine; Charles University and University Hospital Motol, Praha; Czech Pediatric Hematology Working Group (CPH); Prague, Czech Republic.
- 700 1_
- $a Zecca, Marco $u Pediatric Hematology-Oncology; Fondazione IRCCS;Policlinico San Matteo; Pavia, Italy.
- 700 1_
- $a Hasle, Henrik $u Department of Pediatrics; Aarhus University Hospital Skejby; Aarhus, Denmark.
- 700 1_
- $a Schmugge, Markus $u Division of Hematology; University Children's Hospital; Zurich, Switzerland.
- 700 1_
- $a van den Heuvel-Eibrink, Marry M $u Department of Pediatric Oncology-Hematology; Erasmus Medical Center; Rotterdam, The Netherlands; Dutch Children's Oncology Group; The Hague, Netherlands.
- 700 1_
- $a Locatelli, Franco $u Department of Pediatric Hematology-Oncology; IRCCS Ospedale Bambino Gesu; Rome, Italy; University of Pavia; Pavia, Italy.
- 700 1_
- $a Niemeyer, Charlotte M $u The German Cancer Consortium; Heidelberg, Germany; Division of Pediatric Hematology-Oncology; University Medical Center; Freiburg, Germany.
- 700 1_
- $a Flotho, Christian $u The German Cancer Consortium; Heidelberg, Germany; Division of Pediatric Hematology-Oncology; University Medical Center; Freiburg, Germany.
- 700 1_
- $a Plass, Christoph $u Division of Epigenomics and Cancer Risk Factors (C010); German Cancer Research Center; Heidelberg, Germany; The German Cancer Consortium; Heidelberg, Germany.
- 773 0_
- $w MED00180218 $t Epigenetics. $x 1559-2308 $g Roč. 9, č. 9 (2014), s. 1252-60
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25147919 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20230331095210 $b ABA008
- 999 __
- $a ok $b bmc $g 1083446 $s 906101
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 9 $c 9 $d 1252-60 $i 1559-2308 $m Epigenetics. $n Epigenetics $x MED00180218
- LZP __
- $a Pubmed-20150709